- Home
- ISPR vs ACOG Comparison
ISPR vs ACOG Comparison
Compare ISPR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- ACOG
- Stock Information
- Founded
- ISPR 2010
- ACOG 2000
- Country
- ISPR United States
- ACOG Canada
- Employees
- ISPR N/A
- ACOG N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- ACOG
- Sector
- ISPR Health Care
- ACOG
- Exchange
- ISPR Nasdaq
- ACOG Nasdaq
- Market Cap
- ISPR 126.0M
- ACOG 149.0M
- IPO Year
- ISPR 2023
- ACOG N/A
- Fundamental
- Price
- ISPR $2.40
- ACOG $6.50
- Analyst Decision
- ISPR Strong Buy
- ACOG Strong Buy
- Analyst Count
- ISPR 1
- ACOG 1
- Target Price
- ISPR $7.50
- ACOG $18.00
- AVG Volume (30 Days)
- ISPR 45.3K
- ACOG 90.6K
- Earning Date
- ISPR 11-12-2025
- ACOG 11-14-2025
- Dividend Yield
- ISPR N/A
- ACOG N/A
- EPS Growth
- ISPR N/A
- ACOG N/A
- EPS
- ISPR N/A
- ACOG N/A
- Revenue
- ISPR $127,494,304.00
- ACOG $4,586,341.00
- Revenue This Year
- ISPR $60.96
- ACOG N/A
- Revenue Next Year
- ISPR $23.96
- ACOG $101.16
- P/E Ratio
- ISPR N/A
- ACOG N/A
- Revenue Growth
- ISPR N/A
- ACOG N/A
- 52 Week Low
- ISPR $2.06
- ACOG $3.75
- 52 Week High
- ISPR $7.47
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- ISPR 41.40
- ACOG 35.21
- Support Level
- ISPR $2.10
- ACOG $6.55
- Resistance Level
- ISPR $2.32
- ACOG $6.95
- Average True Range (ATR)
- ISPR 0.17
- ACOG 0.41
- MACD
- ISPR -0.00
- ACOG -0.00
- Stochastic Oscillator
- ISPR 27.53
- ACOG 0.00
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.